BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Acella Pharmaceuticals, LLC Signs License Agreement for U.S. Marketing Rights to Generic Antibiotic


6/7/2010 11:57:07 AM

ALPHARETTA, Ga., June 7 /PRNewswire/ -- Acella Pharmaceuticals has signed a licensing agreement for the U.S. marketing rights to a generic version of an intravenous administered broad-spectrum antibiotic.

The Abbreviated New Drug Application (ANDA) was filed with the FDA in November 2009, and is expected to gain approval within the next 24 months.

Under the terms of the agreement, Acella Pharmaceuticals will market, sell and distribute the generic product in the U.S. Mark Pugh, CEO states, "This strategic move into the institutional marketplace serves to diversify Acella Pharmaceuticals' product line and customer base while providing an exciting new avenue for company growth."

Acella Pharmaceuticals is a specialty pharmaceutical company committed to accelerating the health care solution by bringing quality affordable products to customers and patients.

SOURCE Acella Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES